A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

Phase 3 Completed 720 enrolled Novo Nordisk A/S

RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents

Timeline

Start: 2017-05-26
Primary completion: 2019-06-14
Completion: 2019-07-13

Publications

Results Wang W, Agner BFR, Luo B, Liu L, Liu M, Peng Y, Qu S, Stachlewska KA, Wang G, Yuan G, Zhang Q, Ning G. DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs. J Diabetes. 2022 Jun;14(6):401-413. doi: 10.1111/1753-0407.13286.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Insulin degludec/liraglutide	Unknown	—	Subcutaneous
Subject	Liraglutide	Peptide	—	Subcutaneous
Subject	insulin degludec	Protein / enzyme biologic	—	Subcutaneous

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

Summary

Timeline

Publications

Drugs

Indications